MedTrace Logo

A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)

NCT01077804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7585

Last updated 2017-09-15

Study results available
· View outcomes & findings →

Summary

The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAX® \[Varicella Virus Vaccine Live (Oka/Merck)\] and to assess the impact of the vaccine on the epidemiology of varicella and herpes zoster.

Conditions

  • Varicella
  • Herpes Zoster

Sponsors & Collaborators

Principal Investigators

  • Roger Baxter · Kaiser Permanente

Eligibility

Min Age
12 Months
Max Age
23 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1995-06-01
Primary Completion
2010-09-01
Completion
2010-11-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01077804 on ClinicalTrials.gov